Selective dopamine D3 receptor antagonists. A decade of progress: 1997-2007

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 8, 2008, Pages 821-840

  Micheli, Fabrizio ^a   Heidbreder, Christian ^b  

^a GSK   (Italy)

^b Philip Morris USA   (United States)

Author keywords

7TM; Addiction; D3; Dopamine; Impulse control disorders; Receptor; Schizophrenia; Selective antagonist

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; NAFADOTRIDE; RACLOPRIDE;

DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GENETIC POLYMORPHISM; IMPULSE CONTROL DISORDER; NONHUMAN; PREMATURE EJACULATION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; RENAL PROTECTION; REVIEW; SCHIZOPHRENIA; STIMULUS RESPONSE;

EID: 51049090956     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.8.821     Document Type: Review

References (198)

1. 3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 2005;49:77-105
2. Allman JM, Watson KK, Tetreault NA, Hakeem AY. Intuition and autism a possible role for von Economo neurons. Trends Cogn Sci 2005;9:367-73
3. von Economo C, Koskinas GN. The cytoarchitectonic of the human cerebral cortex. London: Oxford University Press; 1929
4. Nimchinsky EA, Vogt BA, Morrison JH, Hof PR. Spindle neurons of the human anterior cingulate cortex. J Comp Neurol 1995;355:27-37
5. Nimchinsky EA, Gilissen E, Allman JM, et al. A neuronal morphologic type unique to humans and great apes. Proc Natl Acad Sci USA 1999;96:5268-73
6. Singer T, Seymour B, O'Doherty J, et al. Empathy for pain involves the affective but not sensory components of pain. Science 2004;303:1157-62
7. Shin L, Dougherty D, Orrb S, et al. Activation of anterior paralimbic structures during guilt-related script-driven imagery. Biol Psychiatry 2000;48:43-50
8. Berthoz S, Armony JL, Blair RJR, Dolan RJ. An fMRI study of intentional and unintentional (embarrassing) violations of social norms. Brain 2002;125:1696-708
9. Spence SA, Hunter MD, Farrow TF, et al. A cognitive neurobiological account of deception evidence from functional neuroimaging. Philos Trans R Soc Lond B Biol Sci 2004;359:1755-62
10. Naqvi NH, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking. Science 2007;315:531-4
11. Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996;16:6100-6
12. Mash DC. D3 receptor binding in human brain during cocaine overdose. Mol Psychiatry 1997;2:5-6
13. Segal DM, Moraes CT, Mash DC. Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 1997;45:335-9
14. Mash DC, Staley JK. D3 dopamine and 0kappa opioid receptor alterations in human brain of cocaine-overdose victims. Ann NY Acad Sci 1999;877:507-22
15. Le Foll B, Francès H, Diaz J, et al. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002;15:2016-26
16. 3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 2003a;47:176-83
17. 3 receptor ligands. Mol Psychiatry 2003b;8:225-30
18. Neisewander JL, Fuchs RA, Tran-Nguyen LT, et al. Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 2004;29:1479-87
19. Spangler R, Goddard NL, Avena NM, et al. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine. Brain Res Mol Brain Res 2003;111:74-83
20. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002;22:9595-603
21. 3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 2004;176:57-65
22. 3 receptors. Synapse 2005;57:17-28
23. 3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005; 21:3427-38
24. 3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 2006;31:1393-405
25. 3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007;10:167-81
26. Martelle JL, Claytor R, Ross JT, et al. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3 dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2- carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl) piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 2007;321:573-82
27. Micheli F, Bonanomi G, Blaney FE, et al. 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 2007;50:5076-89
28. Di Ciano P. Drug seeking under a second-order schedule of reinforcement depends on dopamine D3 receptors in the basolateral amygdala. Behav Neurosci 2008;122:129-39
29. 3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003;28:1272-80
30. 3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006;9:585-602
31. 3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007;559:173-9
32. 3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 2005;81:190-7
33. 3 receptor plays an essential role in alcohol-seeking and relapse. FASEB 2006;20:2223-33
34. 3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007;12:35-50
35. Spiller K, Xi ZX, Peng XQ, et al. The selective dopamine D(3) receptor antagonists SB-277011A and NGB 2904 and the putative partial D(3) receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology (Berl) 2008;196:533-42
36. 3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse 2003;48:154-6
37. 3 receptors in the addictive properties of ethanol. Drugs Today 2004;40:355-65
38. Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 2005;10:917-25
39. Le Foll B, Goldberg SR, Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 2005;49:525-41
40. Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 2005;48:3663-79
41. Le Foll B, Goldberg SR, Sokoloff P. Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 2007;16:45-57
42. 3 receptor antagonists: a review 2001-2005. Recent Patents CNS Drug Discov 2006; 1:271-88
43. Xi ZX, Gardner EL. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev 2007;3:240-59
44. Schwarz AJ, Gozzi A, Reese T, et al. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imaging 2007;25:811-20
45. Narendran R, Slifstein M, Guillin O, et al. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 2006;60:485-95
46. Ginovart N, Willeit M, Rusjan P, et al. Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007;27:857-71
47. Rabiner A, Slifstein M, Gunn RN, et al. D3 receptor quantification with [11C]-(+)-PHNO PET. Proceedings of the 46th Annual Meeting of the American College of Neuropsychopharmacology; 9 - 13 December 2007; Boca Raton (FL)
48. Cloninger CR, Sigvardsson S, Bohman M, Childhood personality predicts alcohol abuse in young adults. Alcohol Clin Exp Res 1988;12:494-505
49. Thome J, Weijers HG, Wiesbeck GA, et al. Dopamine D3 receptor gene polymorphism and alcohol dependence: relation to personality rating. Psychiatr Genet 1999;9:17-21
50. Meszaros K, Lenzinger E, Hornik K, et al. The Tridimensional Personality Questionnaire as a predictor of relapse in detoxified alcohol dependents. The European Fluvoxamine in Alcoholism Study Group. Alcohol Clin Exp Res 1999;23:483-86
51. Limosin F, Romo L, Batel P, et al. Association between dopamine receptor D3 gene Ball polymorphism and cognitive impulsiveness in alcohol-dependent men. Eur Psychiatry 2005;20:304-6
52. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003;49:226-31
53. Leyton M, Boileau I, Benkelfat C, et al. Amphetamine-induced increases in extracellular dopamine, drug wanting and novelty seeking: a PET/ [11C]raclopride study in healthy men. Neuropsychopharmacology 2002;27:1027-35
54. Vandenbergh DJ, O'Connor RJ, Grant MD, et al. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addict Biol 2007;12:106-16
55. Richtand NM. Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology 2006;31:2368-75
56. Pritchard LM, Logue AD, Taylor BC, et al. Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty. Brain Res Bull 2006;70:296-303
57. 3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 1997;54:225-32
58. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Brain Res Rev 2000;31:277-87
59. Mogenson GJ, Yang CR, Yim CY. Influence of dopamine on limbic inputs to the nucleus accumbens. Ann NY Acad Sci 1988;537:86-100
60. Meincke U, Morth D, Voss T, et al. Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis-a longitudinal study. Eur Arch Psychiatry Clin Neurosci 2004;254:415-21
61. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000;294:1154-65
62. Zhang M, Ballard ME, Unger LV, et al. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine Behav Brain Res 2007;182:1-11
63. Zhang M, Ballard ME, Kohlhaas KL, et al. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficit induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006;31:1382-92
64. Chagas-Martinich L, Carey RJ, Carrera MP. 7-OH-DPAT effects on latent inhibition: low dose facilitation but high dose blockade: implications for dopamine receptor involvement in attentional processes. Pharmacol Biochem Behav 2007;86:441-8
65. Swerdlow NR, Geyer MA, Shoemaker JM, et al. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 2006;31:506-15
66. Patterson JV, Hetrick WP, Boutros NN, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008;158:226-47
67. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607-19
68. 3 receptor antagonist. J Med Chem 2003;46:4952-64
69. Millan MJ, Svenningson P, Ashby CR Jr, et al. S33138, a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioural characterisation in vivo. J Pharmacol Exp Ther 2008;324:600-11
70. Southam E, Lloyd A, Jennings CA, et al. Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain. Brain Res 2007;1149:50-7
71. Robertson GS, Lee CJ, Sridhar K, et al. Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004;20:3189-94
72. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27
73. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1081-90
74. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86-9
75. Dawson NM, Hamid EH, Egan MF, Meredith GE. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001;39:70-81
76. Dubertret C, Gorwood P, Ades J, et al. Meta-analysis of Drd3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians, Am J Med Genet 1998;81:318-22
77. 3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 2003;13:1-12
78. 3 receptor-gene-not-associated-with-symptomatology-of-major-psychoses. Am J Med Genet 1999;88:476-80
79. 3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis, Psychiatr Genet 2003;13:1-12
80. Krebs MO, Sautel F, Bourdel MC, et al. Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol Psychiatry 1998;3:337-41
81. Ebstein RP, Macciardi F, Heresco-Levi U, et al. Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum Hered 1997;47:6-16
82. Griffon N, Crocq MA, Pilon C, et al. Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996;67:63-70
83. Nimgaonkar VL, Sanders AR, Ganguli R, et al. Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. Am J Med Genet 1996;67:505-14
84. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-19
85. Gourion D, Goldberger C, Leroy S, et al. Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. Neuroreport 2005;16:1407-10
86. Lorenzo CV, Baca-Garcia E, Hernandez MD, et al. No association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and schizophrenia in a Spanish sample. Am J Med Genet B Neuropsychiatr Genet 2007;144:344-46
87. Fathalli F, Rouleau GA, Xiong L, et al. No association between the DRD3 Ser9Gly polymorphism and schizophrenia. Schizophr Res 2008;98:98-104
88. Talkowski ME, Mansour H, Chowdari KV, et al. Novel, replicated associations between dopamine D3 receptor gene polymorphisms and schizophrenia in two independent samples. Biol Psychiatry 2006;60:570-7
89. Millan MJ, Gobert A, Newman-Tancredi A, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors. I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1048-62
90. Millan MJ, Dekeyne A, Rivet JM, et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors. II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 2000;293:1063-73
91. Gyertyán I, Sághy K. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol 2007;572:171-4
92. Siuciak JA, Fujiwara RA. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology 2004;175:163-9
93. Millan MJ, Loiseau F, Dekeyne A, et al. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c] pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008;324:1212-26
94. Swain SN, Beuk J, Heidbreder CA, Beninger RJ. Role of dopamine D(3) receptors in the expression of conditioned fear in rats. Eur J Pharmacol 2008;579:167-76
95. Sarter M, Nelson CL, Bruno JP. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 2005;31:117-38
96. Ichikawa J, Dai J, O'Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39
97. Lacroix LP, Hows ME, Shah AJ, et al. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology 2003;28:839-49
98. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci 2005;6:48-56
99. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004;28:771-84
100. Lacroix LP, Ceolin L, Zocchi A, et al. Selective dopamine D(3) receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J Neurosci Methods 2006;157:25-31
101. Millan MJ, Di Cara B, Dekeyne A, et al. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 2007;100:1047-61
102. 3 receptors enhances frontocortical cholinergic transmission and cognitive function in rats [abstract 776.4]. 34th Ann Meet Soc Neurosci; 2004; San Diego, CA
103. Drescher KU, Behl B, Freeman AS, et al. ABT-127, a new selective dopamine D3 receptor antagonist: neurochemical and electrophysiological studies in vivo [abstract 913.19]. 35th Ann Meet Soc Neurosci; 12 - 16 Nov 2005; Washington, DC
104. Millan MJ. Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia. Med Sci (Paris) 2005;21:434-42
105. Glickstein SB, Desteno DA, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex 2005;15:1016-24
106. Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance of memory-impaired rats. Psychopharmacology 2005;179:567-75
107. Bézard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-7
108. 3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol 2004;188:128-38
109. 3 receptor protein in the rat kidney. Hypertension 1998;32:886-95
110. Luippold G, Beilharz M, Wehrmann M, et al. Effect of dopamine D3 receptor blockade on renal function and glomerular size in diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 2005;371:420-7
111. Gross ML, Koch A, Mühlbauer B, et al. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab Invest 2006;86:262-74
112. Kitrey ND, Clément P, Bernabé J, et al. Microinjection of the preferential dopamine receptor D3 agonist 7-hydroxy-N,N-di-n-propylaminotetralin hydrobromide into the hypothalamic medial preoptic area induced ejaculation in anesthetized rats. Neuroscience 2007;149:636-41
113. Clément P, Bernabé J, Denys P, et al. Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino) tetralin in anesthetized rats. Neuroscience 2007;145:605-10
114. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 2001;46:3-26
115. Neurogen Corp. WO9710229; 1997
116. Neurogen Corp. US6015900; 2000
117. Neurogen Corp. WO9731916; 1997
118. Neurogen Corp. WO9734884; 1997
119. Neurogen Corp. WO9734889; 1997
120. Neurogen Corp. WO9738989; 1997
121. Neurogen Corp. WO9738990; 1997
122. Neurogen Corp. US6175015; 2001
123. Smithklinebeecham PLC. WO9743262; 1997
124. Smithklinebeecham PLC. WO9806699; 1998
125. Smithklinebeecham PLC. WO9849145; 1998
126. Smithklinebeecham PLC. WO9850363; 1998
127. Smithklinebeecham PLC. WO9851671; 1998
128. Smithklinebeecham PLC. WO9850364; 1998
129. Smithklinebeecham PLC. WO9959974; 1999
130. Smithklinebeecham PLC. WO9964412; 1999
131. Smithklinebeecham PLC. WO0021950; 2000
132. Smithklinebeecham PLC. WO0024717; 2000
133. Smithklinebeecham PLC. WO0021951; 2000
134. Smithklinebeecham PLC. WO0240471; 2002
135. Smithklinebeecham PLC. CA2342434; 2001
136. Glaxo Group Limited. WO2005080382; 2005
137. Glaxo Group Limited. WO2005087764; 2005
138. Glaxo Group Limited. WO2005118549; 2005
139. Glaxo Group Limited. WO2005123717; 2005
140. Glaxo Group Limited. WO2006002928; 2006
141. Glaxo Group Limited. WO2006108700; 2006
142. Glaxo Group Limited. WO2007022936; 2007
143. Glaxo Group Limited. WO2007022933; 2007
144. Glaxo Group Limited. WO2006108701; 2006
145. Glaxo Group Limited. WO2006136223; 2006
146. Glaxo Group Limited. WO2006133946; 2006
147. Glaxo Group Limited. WO2006133945; 2006
148. Glaxo Group Limited. WO2007022935; 2007
149. Glaxo Group Limited. WO2007022934; 2007
150. Glaxo Group Limited. WO2007113258; 2007
151. Glaxo Group Limited. WO2007113232; 2007
152. Glaxo Group Limited. WO2007113260; 2007
153. Glaxo Group Limited. WO2007125061; 2007
154. BASF AK-Tiengesellschaft. WO9725324; 1997
155. BASF AG. US2002143179; 2002
156. BASF AG. DE19728996; 1999
157. BASF AK-Tiengesellschaft. WO0042036; 2000
158. BASF AK-Tiengesellschaft. WO0042037; 2000
159. BASF AG. DE19922443; 2000
160. Abbott Laboratories. WO03002543; 2003
161. Abbott GMBH & Co. KG. DE10311065; 2004
162. Abbott GMBH & Co. KG. WO2005056546; 2005
163. Abbott GMBH & Co. KG. WO2005118558; 2005
164. Abbott GMBH & Co. KG. WO2005118571; 2005
165. Abbott GMBH & Co. KG. DE10304870; 2004
166. Abbott GMBH & Co. KG. EP1484330; 2004
167. Abbott GMBH & Co. KG. US2004259882; 2004
168. Abbott GMBH & Co. KG. WO2006015842; 2006
169. Abbott GMBH & Co. KG. US2004204422; 2004
170. Abbott GMBH & Co. KG. US2005137186; 2005
171. Abbott GMBH & Co. KG. WO2005058328; 2005
172. Abbott GMBH & Co. KG. US2005137186; 2005
173. Abbott GMBH & Co. KG. WO2006040176; 2006
174. Abbott GMBH & Co. KG. WO2006040180; 2006
175. Abbott GMBH & Co. KG. WO2006040177; 2006
176. Abbott GMBH & Co. KG. WO2006040182; 2006
177. Abbott GMBH & Co. KG. WO2006040179; 2006
178. Abbott GMBH & Co. KG. WO2006040178; 2006
179. Abbott GMBH & Co. KG. WO2006058753; 2006
180. Abbott GMBH & Co. KG. US2006160809; 2006
181. Abbott GMBH & Co. KG. WO2007118859; 2007
182. Abbott GMBH & Co. KG. DE102004061593; 2006
183. Pharmacia & Upjohn Company. WO9745403; 1997
184. Pharmacia & Upjohn Company. US5936000; 1999
185. Pharmacia & Upjohn Company. WO9958499; 1999
186. Pfizer Products, Inc. EP1211247; 2002
187. Aventis Pharmaceuticals, Inc. WO02066446; 2002
188. Aventis Pharmaceuticals, Inc. WO02066468; 2002
189. Aventis Pharmaceuticals, Inc. WO02066469; 2002
190. Richter Gedeon Vegyeszety Gyar RT. WO03028728; 2003
191. Richter Gedeon Vegyeszety Gyar RT. WO03029233; 2003
192. Richter Gedeon Vegyeszety Gyar RT. WO03028725; 2003
193. Bioproject Societe Civile. US2006089364; 2006
194. Bioproject Societe Civile. FR2878524; 2006
195. Friedrich-Alexander Universitat Erlangen-Nurnberg. WO2004004729; 2004
196. Schwarz Pharma AG. WO2006015737; 2006
197. Schwarz Pharma AG. DE102004063797; 2006
198. Gov't of the USA. WO2004024878; 2004